EFG Asset Management North America Corp. Has $5.73 Million Stake in Glaukos Corporation $GKOS

EFG Asset Management North America Corp. raised its stake in Glaukos Corporation (NYSE:GKOS) by 4.5% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 55,459 shares of the medical instruments supplier’s stock after purchasing an additional 2,383 shares during the period. EFG Asset Management North America Corp. owned 0.10% of Glaukos worth $5,730,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Alliancebernstein L.P. increased its holdings in Glaukos by 56.5% in the 1st quarter. Alliancebernstein L.P. now owns 1,277,539 shares of the medical instruments supplier’s stock worth $125,735,000 after acquiring an additional 461,386 shares during the last quarter. AustralianSuper Pty Ltd purchased a new stake in Glaukos in the 2nd quarter worth about $41,946,000. William Blair Investment Management LLC increased its holdings in Glaukos by 52.4% in the 2nd quarter. William Blair Investment Management LLC now owns 1,136,095 shares of the medical instruments supplier’s stock worth $117,347,000 after acquiring an additional 390,805 shares during the last quarter. Braidwell LP increased its holdings in Glaukos by 116.2% in the 1st quarter. Braidwell LP now owns 624,435 shares of the medical instruments supplier’s stock worth $61,457,000 after acquiring an additional 335,559 shares during the last quarter. Finally, Nuveen LLC purchased a new stake in Glaukos in the 1st quarter worth about $31,474,000. 99.04% of the stock is currently owned by institutional investors and hedge funds.

Glaukos Stock Performance

Shares of GKOS stock opened at $85.74 on Wednesday. The stock has a fifty day moving average of $85.18 and a 200 day moving average of $91.49. Glaukos Corporation has a 52 week low of $73.16 and a 52 week high of $163.71. The firm has a market capitalization of $4.92 billion, a price-to-earnings ratio of -55.67 and a beta of 0.76. The company has a quick ratio of 4.69, a current ratio of 5.51 and a debt-to-equity ratio of 0.09.

Glaukos (NYSE:GKOS) last announced its quarterly earnings results on Wednesday, October 29th. The medical instruments supplier reported ($0.16) EPS for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.11. The company had revenue of $133.54 million during the quarter, compared to analyst estimates of $122.55 million. Glaukos had a negative return on equity of 7.53% and a negative net margin of 18.65%.The firm’s revenue was up 38.1% on a year-over-year basis. During the same quarter last year, the firm posted ($0.28) earnings per share. Glaukos has set its FY 2025 guidance at EPS. As a group, research analysts expect that Glaukos Corporation will post -1.08 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research firms have weighed in on GKOS. Wells Fargo & Company lifted their target price on Glaukos from $120.00 to $122.00 and gave the company an “overweight” rating in a report on Thursday, October 30th. UBS Group lifted their target price on Glaukos from $125.00 to $134.00 and gave the company a “buy” rating in a report on Thursday, July 31st. Citigroup lifted their target price on Glaukos from $110.00 to $113.00 and gave the company a “buy” rating in a report on Thursday, October 30th. The Goldman Sachs Group assumed coverage on shares of Glaukos in a report on Wednesday, October 1st. They issued a “buy” rating and a $103.00 price target on the stock. Finally, Stifel Nicolaus set a $115.00 price target on shares of Glaukos in a report on Monday, October 27th. One analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $118.62.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.